FDA expands use of Xgeva to include giant cell tumor of the bone

The FDA approved the use of Amgen's Xgeva, or denosumab, to treat adults and some adolescents with giant cell tumor of the bone that is unresectable or where surgery is likely to result in severe morbidity. The approval makes denosumab the first and only approved drug for this condition. Xgeva, a fully human monoclonal antibody, was previously approved for treatment of osteoporosis and for prevention of skeletal-related events in adults with bone metasteses and solid tumors.

View Full Article in:

Pharmaceutical Business Review Online · Medscape (free registration) · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ